Recommended dosing in PV1
JAKAVI is to be given orally twice a day (BID)1
Recommended dose
- Starting dose for most patients: 10 mg BID1
- Maximum dose: 25 mg BID1
Available strengths of tablets1
Tablets shown are not actual size.
Important considerations for starting therapy with JAKAVI1
- A complete blood cell count must be performed before initiating therapy with JAKAVI
- There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and 100,000/mm3
- The starting dose should not be increased during the first 4 weeks of treatment
Dose modifications
- Doses may be titrated based on safety and efficacy1
Dose adjustments during treatment by blood count1
Dose adjustments based on response to treatment1
The starting dose should not be increased during the first 4 weeks of treatment, and thereafter no more frequently than at 2-week intervals. Maximum dose is 25 mg BID.
Treatment duration
- Treatment may be continued as long as the benefit/risk ratio remains positive1
